Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINTÂŽ particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Source
No articles found.
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discover...
miRagen Therapeutics, Inc., is a clinical stage...
We are a commercial-stage biotech company focused on harnessing the inherent biolo...
We are a commercial-stage biotech company focus...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Akero aims to develop and deliver transformational medicines to patients with high...
Akero aims to develop and deliver transformatio...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are...
iRhythm is a digital healthcare company redefin...
As a leading provider of innovative technologies for the treatment of Atrial Fibri...
As a leading provider of innovative technologie...
Shockwave Medical, headquartered in Santa Clara, California is a medical device co...
Shockwave Medical, headquartered in Santa Clara...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
Join the National Investor Network and get the latest information with your interests in mind.